Last reviewed · How we verify
Nicardipine + Verapamil + Nitroglycerin
This combination reduces cardiac workload and improves coronary blood flow by blocking calcium channels (nicardipine and verapamil) and dilating blood vessels (nitroglycerin).
This combination reduces cardiac workload and improves coronary blood flow by blocking calcium channels (nicardipine and verapamil) and dilating blood vessels (nitroglycerin). Used for Angina pectoris, Hypertension, Coronary artery disease.
At a glance
| Generic name | Nicardipine + Verapamil + Nitroglycerin |
|---|---|
| Sponsor | Peng Roc Chen, MD |
| Drug class | Combination antihypertensive/antianginal (calcium channel blockers + nitrate) |
| Target | L-type calcium channels (nicardipine, verapamil); soluble guanylate cyclase (nitroglycerin) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Nicardipine and verapamil are calcium channel blockers that reduce cardiac contractility and peripheral vascular resistance, lowering blood pressure and heart rate. Nitroglycerin is a nitrate vasodilator that preferentially dilates coronary arteries and reduces preload on the heart. Together, these agents work synergistically to decrease myocardial oxygen demand and improve coronary perfusion.
Approved indications
- Hypertension
- Angina pectoris
- Coronary artery disease
Common side effects
- Headache
- Dizziness
- Flushing
- Hypotension
- Reflex tachycardia
- Edema
- Constipation
Key clinical trials
- The Intra-arterial Vasospasm Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nicardipine + Verapamil + Nitroglycerin CI brief — competitive landscape report
- Nicardipine + Verapamil + Nitroglycerin updates RSS · CI watch RSS
- Peng Roc Chen, MD portfolio CI